第一章 总则 第一条 为进一步完善公司的治理结构，促进公司的规范运作，切实保护中 小股东及利益相关者的利益，根据《中华人民共和国公司法》(以下简称"《公 司法》")、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司独立董事管理办法》（以下简称"《独立董事管理办法》"）、《上海证券 交易所科创板股票上市规则》（以下简称"《上市规则》"）等法律、法规、规 范性文件和公司章程的相关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应当按 照相关法律法规、《独立董事管理办法》和公司章程及本制度的要求，认真履行 职责，维护公司整体利益，尤其关注中小股东的合法权益不受损害。独立董事应 当独立履行职责，不受公司主要股东、实际控制人、或者其他与公司存在利害关 系的单位或个人的影响。 第二章 独立董事的任职条件 杭州博拓生物科技股份有限公司 独立董事工作制度 杭州博拓生物科技股份有限公司 第四条 独立董事应当具备与其行 ...

杭州博拓生物科技股份有限公司 防范控股股东及其他关联方占用公司资金管理制度 杭州博拓生物科技股份有限公司 防范控股股东及其他关联方占用公司资金管理制度 第一章 总则 第四条 公司按照《上海证券交易所科创板股票上市规则》 《公司章程》及《杭 州博拓生物科技股份有限公司关联交易管理制度》等规定，实施公司与控股股东 及关联方通过采购、销售、相互提供劳务等生产经营环节产生的关联交易行为。 发生关联交易行为后，应及时结算，不得形成非正常的经营性资金占用。 第五条 公司、公司控股子公司及所属分公司不得以下列方式将资金直接或 杭州博拓生物科技股份有限公司 防范控股股东及其他关联方占用公司资金管理制度 间接地提供给控股股东及关联方使用： 第一条 为了建立防止控股股东及关联方占用杭州博拓生物科技股份有限公 司（以下简称"公司"）资金的长效机制，杜绝控股股东及关联方资金占用行为 的发生，根据《中华人民共和国公司法》（以下简称"《公司法》"）等有关法律、 法规、规范性文件和《杭州博拓生物科技股份有限公司章程》 （以下简称"《公司 章程》"）的规定，制定本制度。 第二条 本制度所称资金占用包括但不限于以下方式： （一）经营性资金占用 ...

法有效。 特此公告。 杭州奥泰生物技术股份有限公司董事会 证券代码：688606 证券简称：奥泰生物 公告编号：2025-018 杭州奥泰生物技术股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 19 日 （二） 股东大会召开的地点：浙江省杭州市钱塘区下沙街道乔新路 383 号公司 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 普通股股东人数 55 普通股股东所持有表决权数量 53,229,856 例（%） 普通股股东所持有表决权数量占公司表决权数量的比例（%） 68.3588 注：截至本次股东大会股权登记日的总股本为 79,280,855 股；其中公司回购专用账户中股 份数为 1,412,521 股，不享有股东大会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由董事会召集，由董事长高飞先 ...

Core Viewpoint - The article discusses the recent IPO of CATL, which raised over 50 billion HKD, highlighting the growing interest of tech companies in the Hong Kong stock market due to favorable policies like the "Tech Company Fast Track" [1] Group 1: Eligibility Criteria - Eligible companies include specialized technology firms (e.g., AI, chips, new energy) and biotech companies (e.g., innovative drugs, medical devices), particularly those in early stages or with non-commercialized products [1][4] - Core thresholds include being classified under the Hong Kong Stock Exchange's definitions of "specialized technology" or "biotechnology" [2] - Specialized technology encompasses fields like artificial intelligence, quantum computing, new energy, semiconductors, and autonomous driving [3] Group 2: Application Process - Companies must first assess their eligibility using the self-assessment tool available on the Hong Kong Stock Exchange website [6] - The application process involves signing a Non-Disclosure Agreement (NDA) with the Hong Kong Stock Exchange to ensure confidentiality of submitted materials [8] - A "confidential version" of the application materials must be submitted, including company profile, financial data, and legal documents, while sensitive details remain undisclosed [9][10] Group 3: Review and Feedback - The review team from the Hong Kong Stock Exchange will provide feedback within 30 days, focusing on technical feasibility and compliance [11] - If additional materials are required, they must be submitted through secure channels to prevent information leaks [12] - Confidentiality lasts until the listing hearing, after which the prospectus must be made public [13] Group 4: Specialized Services - Companies can receive one-on-one guidance from the Hong Kong Stock Exchange's expert team, including advice on listing rules and fundraising strategies [14] - Eligible firms may benefit from a fast-track process, reducing the review period to 30 days if they meet specific criteria [15] - Flexible equity structures, such as weighted voting rights (WVR), allow founders to retain control without additional proof of "innovation" [16] Group 5: Common Pitfalls - Companies should avoid vague technical descriptions and ensure transparency in related party transactions [18][20] - Investor relations should be robust, with at least two independent investors involved [21][23] Group 6: Post-Listing Compliance - Companies must disclose significant developments in technology commercialization and research milestones, with certain exemptions for national security-related details [24] - Regular communication with analysts and quarterly updates can help maintain market value [25] - A simplified procedure for issuing new shares is available for specialized technology and biotech companies [26] Group 7: Comparative Analysis - The article compares the IPO processes and requirements across different markets, highlighting the advantages of the Hong Kong Stock Exchange's "Tech Company Fast Track" [27]

Core Insights - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, which will see changes in constituent stocks, leading to stock price fluctuations on May 19, 2025 [1] Group 1: Index Adjustments - The Hang Seng Index (HSI.US) will increase its constituents from 83 to 85, adding Meituan (00300.HK) and ZTO Express (02057.HK) [3] - Following the announcement, ZTO Express's H-shares opened up 2.85% and reached a high of 150 HKD, closing at 149.40 HKD, a 3.97% increase [3] - Meituan opened up 2.12% and is currently up 1.73%, trading at 79.25 HKD, reflecting a 44.62% increase from its IPO price of 54.80 HKD [3] Group 2: Sector Weightings - The financial sector remains the highest weighted industry in the index at 32.42%, with major constituents including HSBC (00005.HK) and Alibaba (09988.HK) [5] - Non-essential and essential consumer sectors account for 29.76%, with Alibaba and BYD (01211.HK) as significant constituents [5] - The information technology sector holds a weight of 17.77%, with Tencent (00700.HK) being a top constituent [5] Group 3: Technology Index Changes - The Hang Seng Tech Index (HSTECH.HK) will include BYD (01211.HK) while excluding Tencent's subsidiary, Reading Group (00772.HK) [6] - Despite being added to the index, BYD's stock fell 0.92% to 430.20 HKD on May 19, 2025 [6] - Reading Group's stock dropped 8.33% after being removed from the index, reflecting a year-to-date decline of 3.97% [6] Group 4: Other Index Movements - The Hang Seng China Enterprises Index will maintain its 50 constituents without changes [8] - The Hang Seng Biotechnology Index will also keep its 50 constituents, with some changes in the stocks included [8] - Newly added stocks to the Hang Seng Composite Index include Brook (00325.HK), Gu Ming (01364.HK), and Mixue Group (02097.HK), which saw price increases following the announcement [9]

Group 1 - The 2025 Asia Healthcare Summit focuses on "Global Collaboration for a Shared Future," bringing together leaders from the healthcare industry to promote investment, financing, and technological innovation in Hong Kong and beyond [2][4] - The summit will feature over 80 international speakers and more than 2,800 participants from 40 countries, showcasing Hong Kong's and Asia's leading advantages in medical technology [2][4] - Key discussions will include optimizing healthcare resource allocation and leveraging innovative technology to enhance accessibility and sustainability of healthcare services [4][7] Group 2 - The "Healthy China 2030" initiative is driving unprecedented transformation in China's healthcare industry, creating vast market potential and business opportunities [7] - Experts from various companies will analyze the latest developments and opportunities in the Chinese healthcare market and innovation ecosystem [7] - The summit will include discussions on artificial intelligence and data technology's impact on the healthcare industry, emphasizing early disease prediction and telemedicine [8][10] Group 3 - A special section on "Silver Health" will address the challenges of an aging population, featuring discussions on breakthroughs in geriatric medicine and investment opportunities in the silver market [11] - The importance of collaboration among stakeholders in the healthcare ecosystem will be emphasized, with discussions on commercial and innovation opportunities in the healthcare industry [12] - The summit will also include various specialized sessions covering topics such as integrative medicine, women's health, orphan drugs, and cancer treatment advancements [14] Group 4 - The forum will host an exhibition area, ASGH Business Hub, featuring over 170 medical technology exhibitors from 13 countries, showcasing cutting-edge technologies like AI and big data [14] - More than 30 global startups will present their projects to potential investors, facilitating connections through one-on-one meetings and providing business consulting services [15] - Last year's forum successfully arranged over 360 meetings for global investment project matching, covering sectors like life sciences, medical devices, and pharmaceuticals [15]

Group 1: Development Opportunities in the Greater Bay Area - The Greater Bay Area is experiencing a clear trend of integration and development despite increasing external uncertainties, with Hong Kong's role as a major offshore RMB center expected to strengthen [1] - Shenzhen's financial bureau plans to enhance cooperation with Hong Kong through project-based initiatives, support listings for Shenzhen and Greater Bay Area companies in Hong Kong, and improve cross-border transaction efficiency [1] Group 2: Financial Innovation and Connectivity - Hong Kong's financial sector possesses unique advantages in financing and investment, aiming to deepen financial connectivity with the mainland through initiatives like Stock Connect and Bond Connect, while promoting RMB internationalization [2] - The Hong Kong government emphasizes the development of innovative finance, green finance, livelihood finance, and Silk Road finance, with significant achievements in innovative finance, becoming the world's second-largest biotech financing center [2] Group 3: Macau's Role and Sector Focus - Macau aims for moderate economic diversification, focusing on traditional Chinese medicine, modern finance, high-tech, and cultural sports, while enhancing connectivity with the mainland and Hong Kong in the financial sector [3] - Macau plans to facilitate cross-border capital flow and digital currency integration, leveraging its connections with Portuguese-speaking countries to promote outbound and inbound business [3] Group 4: Strategies for Addressing Challenges - The Greater Bay Area should enhance technological self-innovation, deepen institutional openness, and strengthen industrial chain resilience, with capital market development being crucial for optimizing financing structures and promoting cross-border capital flow [3]

Core Insights - Chuangxin International Biotechnology (Guangzhou) Co., Ltd. has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Donghai Investment Control's Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [1][2] - The company focuses on personalized treatment, new drug development, and synthetic biology, establishing a comprehensive ecosystem covering the entire lifecycle of organoids [1] - Chuangxin International aims to drive the organoid industry towards intelligent, standardized, and industrialized development, leveraging its advanced technology platform and multi-dimensional data intelligence system [1] Company Overview - Chuangxin International is headquartered in Guangzhou and has established joint R&D centers in Beijing, Shanghai, Macau, and Milan, Italy [1] - The company is recognized as a full-industry chain enterprise in the organoid field, focusing on three strategic directions: precision medicine, new drug development, and intelligent manufacturing [1] Investment Perspective - Yueke Fund highlights the significant application value of Chuangxin International's leading organoid technology in precision medicine and new drug development, aligning with their investment philosophy focused on core technology sectors [2] - Donghai Investment Control emphasizes the company's technological depth and growth potential, viewing this investment as a key part of their strategic layout in the biomedicine sector [2] Future Plans - The CEO of Chuangxin International expresses gratitude for the support from investors and outlines plans to leverage this financing round to enhance core technology research and product innovation [2] - The company aims to create a product matrix in key areas such as organoid intelligent devices, chips, and data intelligence systems, driving technological breakthroughs and industrial upgrades [2]

研究人员表示，虽然距离临床应用还有很长的路，但这项技术已经展现出巨大潜力。想象一下，未来医 生或许能像修复电路一样，精准修复出问题的大脑连接，而不会伤及健康脑区。 美国南加州大学研究团队开发出两款"黑科技"，其能像开关一样选择性且可逆地断开脑细胞之间的连 接。这一成果发表于新一期《eLife》杂志，有望改变脑科学研究，并为治疗癫痫、成瘾和创伤后应激 障碍等神经系统疾病开辟新途径。 （文章来源：科技日报） 团队还开发了两种可按需激活的GFE3工具：一种通过光激活（paGFE3），另一种通过化学信号激活 （chGFE3）。他们表示，借助这些工具，科学家能精准"剪断"特定神经连接，还能让它们重新长回 来。整个过程就像外科手术般精确，只针对目标突触，其他脑细胞完全不受影响。这种可逆、精准的操 作方式，让科学家能更深入地研究记忆、情绪、行为背后的神经机制。 在研究中，该团队从大脑自带的"回收系统"获得灵感，开发出两种分子工具：靶向兴奋性突触（让神经 连接更活跃的突触）的PFE3和靶向抑制性突触（让神经连接更少的突触）的GFE3。突触是神经元之间 在功能上发生联系的部位，也是信息传递的关键部位。 研究人员解释说，在大脑内 ...

Group 1 - At least five Chinese companies plan to conduct IPOs, dual listings, or placements in Singapore within the next 12 to 18 months, indicating a trend of Chinese firms seeking to diversify their capital sources in Southeast Asia [1] - The companies planning to list in Singapore span various industries, including an energy company, a medical group, and a Shanghai-based biotechnology firm [1] - Some companies may aim to raise approximately $100 million through listings on the Singapore mainboard [1] Group 2 - This trend is expected to boost the performance of the Singapore Exchange (SGX), which has struggled to attract large listings and increase trading volume [2] - In 2024, the SGX has only recorded four IPOs, and it is not typically the first choice for Chinese companies looking to list overseas, with Hong Kong being more favored [2] - To enhance market attractiveness, Singapore has introduced a series of revitalization measures for the stock market, including tax incentives and simplified listing processes [2] Group 3 - Observers note that Singapore's local investors are relatively conservative, and the stricter listing requirements may hinder the exchange's ability to close the gap with Hong Kong in the short term [2] - Singapore is recognized as a world-class financial center with mature legal and regulatory frameworks, which can be appealing to Chinese companies [2] - Companies need to be aware of market risks, regulatory differences, and valuation recognition when considering listings in Singapore [2]